Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission

Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention... EDITORIAL Antiretroviral therapy for naı¨ve and for treatment-experienced HIV patients, and prevention of HIV transmission Francisco Antunes Head of Infectious Diseases Department, Hospital de Santa Maria – CHLN, EPE, uninfected individuals globally will be an enormous and Full Professor at Faculty of Medicine of Lisbon, Portugal challenge, and turning treatment into prevention will Correspondence to Francisco Antunes, Infectious Diseases Department, Hospital reduce the transmission of HIV, but a population-level de Santa Maria, Av. Egas Moniz, 1649-035 Lisbon, Portugal benefit has still not been proven. So, the need for an HIV Tel: +351 21 780 52 70; fax: +351 21 79 76 248; e-mail: ip231874@sapo.pt vaccine remains as pressing as ever, being a major public Current Opinion in HIV and AIDS 2011, 6 (suppl 1):S1–S2 health priority. Recently, three HIV vaccine products This special issue of Current Opinion on HIV and AIDS have been tested in clinical efficacy trials – VaxGen, is devoted to recent advances in antiretroviral therapy STEP, and RV144 [1–4]. The results of the first two trials (ART), for naı¨ve and treatment-experienced HIV were disappointing, and therefore these were stopped patients, and prevention of HIV transmission. prematurely, despite the induction of significant antibody titres against HIV or http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission

Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/antiretroviral-therapy-for-na-iuml-ve-and-for-treatment-experienced-5NjvRFMMip

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1746-630X
eISSN
1746-6318

Abstract

EDITORIAL Antiretroviral therapy for naı¨ve and for treatment-experienced HIV patients, and prevention of HIV transmission Francisco Antunes Head of Infectious Diseases Department, Hospital de Santa Maria – CHLN, EPE, uninfected individuals globally will be an enormous and Full Professor at Faculty of Medicine of Lisbon, Portugal challenge, and turning treatment into prevention will Correspondence to Francisco Antunes, Infectious Diseases Department, Hospital reduce the transmission of HIV, but a population-level de Santa Maria, Av. Egas Moniz, 1649-035 Lisbon, Portugal benefit has still not been proven. So, the need for an HIV Tel: +351 21 780 52 70; fax: +351 21 79 76 248; e-mail: ip231874@sapo.pt vaccine remains as pressing as ever, being a major public Current Opinion in HIV and AIDS 2011, 6 (suppl 1):S1–S2 health priority. Recently, three HIV vaccine products This special issue of Current Opinion on HIV and AIDS have been tested in clinical efficacy trials – VaxGen, is devoted to recent advances in antiretroviral therapy STEP, and RV144 [1–4]. The results of the first two trials (ART), for naı¨ve and treatment-experienced HIV were disappointing, and therefore these were stopped patients, and prevention of HIV transmission. prematurely, despite the induction of significant antibody titres against HIV or

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Dec 1, 2011

There are no references for this article.